Thyroid Nodule Follow-Up Guide: When Is Surgery Needed?

Introduction

Thyroid nodules are one of the most common endocrine disorders in clinical practice. With the widespread use of high-resolution ultrasound, their detection rate has reached 20%-76%, of which approximately 90%-95% are benign. However, facing the term "nodule," many patients still fall into anxiety: Could it become cancerous? How often should I have follow-ups? Under what circumstances is surgery necessary? This article, based on the latest consensus from the American Thyroid Association (ATA) and the Thyroid Cancer Professional Committee of the Chinese Anti-Cancer Association, breaks down the decision-making logic for follow-up and surgery, so you no longer need to "panic at the mention of nodules."

Step 1: Understanding the Ultrasound Report—TI-RADS Classification Is Key

Thyroid ultrasound is the cornerstone of nodule evaluation. The currently internationally used Thyroid Imaging Reporting and Data System (TI-RADS) classifies nodules into categories 1-5:

TI-RADS 1-2: Extremely likely benign (malignancy risk <2%), no aspiration needed; annual ultrasound follow-up is sufficient.

TI-RADS 3: Likely benign (malignancy risk <5%); follow-up ultrasound in 6-12 months is recommended. If the nodule grows (volume increase ≥50% or diameter increase ≥2 mm), aspiration should be considered.

TI-RADS 4: Suspicious for malignancy (risk 5%-80%), with 4a having lower risk (5%-10%), 4b (10%-50%), and 4c (50%-80%). Fine-needle aspiration (FNA) is recommended for 4b and above.

TI-RADS 5: Highly suspicious for malignancy (risk >80%); direct surgery or aspiration for diagnosis is recommended.

Key ultrasound features include: solid hypoechoic appearance, microcalcifications, irregular margins or extrathyroidal extension, and a taller-than-wide shape (aspect ratio >1). If these descriptions appear in the report, heightened vigilance is required.

Step 2: Fine-Needle Aspiration—The "Gold Standard" for Deciding Surgery

Fine-needle aspiration biopsy (FNA) is the "gold standard" for preoperative diagnosis, with a sensitivity of approximately 83% and specificity of approximately 92%. Indications include:

Nodule diameter >1 cm with TI-RADS ≥4;

Nodule diameter >1.5 cm with TI-RADS 3;

Nodules of any size with high-risk history (e.g., childhood head or neck radiation exposure, family history of thyroid cancer, or incidental hypermetabolic nodules detected on PET-CT).

Aspiration results are classified according to the Bethesda system (categories I-VI):

Bethesda II (Benign): Continue follow-up with ultrasound in 6-12 months; no surgery needed.

Bethesda III/IV (Atypia of undetermined significance/Follicular lesion): Approximately 20%-30% ultimately prove malignant. Molecular marker testing (e.g., BRAF V600E mutation, RAS mutation) can aid decision-making, or repeat aspiration may be considered.

Bethesda V (Suspicious for malignancy): Malignancy probability 60%-75%; surgery is recommended.

Bethesda VI (Malignant): Malignancy probability >95%; direct surgery is indicated.

Step 3: Surgical Indications—When to "Cut When Necessary"

Surgery is not the only option for nodules, but the following situations warrant active consideration:

Confirmed or highly suspected malignancy: Bethesda V/VI, or indeterminate aspiration with highly suspicious ultrasound features.

Compressive symptoms caused by the nodule: Such as dysphagia, hoarseness, breathing difficulty, or significant nodule growth (diameter increase ≥2 mm with volume increase ≥50% within 6-12 months).

Retrosternal nodule location: May compress the trachea; surgery is often recommended even if benign.

Concurrent high-risk factors: Age <20 or >70 years, male sex, history of neck radiation, or family history of thyroid cancer—these groups have significantly elevated malignancy risk.

Thyroid dysfunction: For example, if the nodule is a hyperfunctioning adenoma (toxic nodule), surgery or radioactive iodine therapy may be considered.

For micropapillary carcinoma (diameter ≤1 cm, no lymph node metastasis or extrathyroidal extension), according to the 2015 ATA guidelines, "active surveillance" may also be chosen, involving ultrasound follow-up every 6-12 months; approximately 90% of microcarcinomas show no significant progression within 5 years. However, this strategy requires high patient compliance and access to regular follow-up.

Step 4: Follow-Up Rhythm—Not Too Frequent, But Not Missed

Benign nodules (TI-RADS ≤3 with benign aspiration): Ultrasound every 12-24 months; if no change for 2 consecutive years, the interval may be extended to 3 years.

TI-RADS 4 nodules (not aspirated or benign on aspiration): Follow-up every 6-12 months, focusing on growth rate and new suspicious features.

Postoperative patients: After thyroid cancer surgery, regular monitoring of thyroglobulin (Tg) and anti-Tg antibodies is required, with neck ultrasound every 6-12 months, adjusted according to recurrence risk stratification (low/intermediate/high).

Note: During follow-up, thyroid-stimulating hormone (TSH) levels should be maintained in an appropriate range. For benign nodules, if TSH is low, levothyroxine suppression therapy may be considered (though evidence is limited); if TSH is normal or elevated, no drug intervention is needed, and follow-up alone suffices.

Recommendations for International Patients

For thyroid nodule patients planning to seek medical care in China, MedBridge Shanghai recommends:

Bring complete records: Previous ultrasound images (preferably in DICOM format), aspiration pathology reports, and thyroid function test results. This avoids repeat examinations, saving time and costs.

Choose an authoritative center: Top thyroid surgery centers in China (e.g., Shanghai Ruijin Hospital, Fudan University Shanghai Cancer Center) have expert teams performing over a thousand surgeries annually, with complication rates (recurrent laryngeal nerve injury, hypoparathyroidism) below 2%.

Clarify the surgical extent: Based on preoperative evaluation, only one lobe may be removed (suitable for solitary microcarcinoma) or total thyroidectomy (for multifocal cancer, bilateral disease, or high recurrence risk). Communicate thoroughly with the primary surgeon to avoid unnecessary extensive resection.

Budget reference: In China, thyroid nodule aspiration costs approximately 2,000-4,000 RMB, and total thyroid cancer surgery costs about 40,000-80,000 RMB (including hospitalization, surgery, anesthesia, and postoperative stay), which is only 1/3 to 1/5 of costs in Western countries. You can obtain a personalized breakdown via cost estimator.

Seamless postoperative follow-up: We can assist in arranging remote follow-up consultations at 6 and 12 months post-surgery, including ultrasound scheduling, Tg testing, and expert video interpretation, ensuring worry-free management after you return home.

Thyroid nodules are not frightening; scientific decision-making matters more than a "one-size-fits-all" approach. If you have concerns about report interpretation or treatment plans, feel free to contact us for multidisciplinary consultation advice. Remember: standardized follow-up is safety, and precise surgery is wisdom.